Deepak Voora

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events
    Deepak Voora
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina Department of Medicine, Duke University, Durham, North Carolina Electronic address
    J Am Coll Cardiol 62:1267-76. 2013
  2. doi request reprint Clinical application of cardiovascular pharmacogenetics
    Deepak Voora
    Duke Institute for Genome Science and Policy, Duke University, Durham, NC 27708, USA
    J Am Coll Cardiol 60:9-20. 2012
  3. pmc Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy
    Deepak Voora
    Institute for Genome Sciences and Policy, Duke University, 905 S Lasalle Dr, DUMC Box 3445, Durham, NC 27710, USA
    J Thromb Thrombolysis 33:246-57. 2012
  4. doi request reprint Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use
    Deepak Voora
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 162:166-72.e1. 2011
  5. pmc Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response
    Deepak Voora
    Division of Cardiovascular Medicine, the Institute for Genome and Science Policy, and the Center for Human Genetics, Duke University, Durham, NC 27708, USA
    Circ Cardiovasc Genet 1:100-6. 2008
  6. doi request reprint The pharmacogenetics of antiplatelet agents: towards personalized therapy?
    Tariq Ahmad
    Division of Cardiology, Duke University School of Medicine, 2400 Pratt Street, DUMC 3850, Durham, NC 27710, USA
    Nat Rev Cardiol 8:560-71. 2011
  7. pmc The SLCO1B1*5 genetic variant is associated with statin-induced side effects
    Deepak Voora
    Division of Cardiovascular Medicine, Duke University Medical Center, Durham, North Carolina 27708, USA
    J Am Coll Cardiol 54:1609-16. 2009
  8. pmc Evaluation of the PharmGKB knowledge base as a resource for efficiently assessing the clinical validity and utility of pharmacogenetic assays
    Kensaku Kawamoto
    Division of Clinical Informatics, Department of Community and Family Medicine, Duke University, Durham, NC, USA
    AMIA Annu Symp Proc 2009:307-11. 2009
  9. ncbi request reprint A hub for bench-to-bedside pharmacogenomic-based research
    Deepak Voora
    Institute for Genome Sciences and Policy, Center for Genomic Medicine, 101 Science Drive, Duke University, DUMC Box 3382, Durham, NC 27708, USA
    Pharmacogenomics 12:1095-8. 2011
  10. ncbi request reprint Preoperative CYP2D6 metabolism-dependent β-blocker use and mortality after coronary artery bypass grafting surgery
    Miklos D Kertai
    Division of Cardiothoracic Anesthesiology and Critical Care, Department of Anesthesiology, Duke University Medical Center, Durham, NC Electronic address
    J Thorac Cardiovasc Surg 147:1368-1375.e3. 2014

Detail Information

Publications11

  1. pmc Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events
    Deepak Voora
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina Department of Medicine, Duke University, Durham, North Carolina Electronic address
    J Am Coll Cardiol 62:1267-76. 2013
    ..The aim of this study was to develop ribonucleic acid (RNA) profiles that could serve as novel biomarkers for the response to aspirin...
  2. doi request reprint Clinical application of cardiovascular pharmacogenetics
    Deepak Voora
    Duke Institute for Genome Science and Policy, Duke University, Durham, NC 27708, USA
    J Am Coll Cardiol 60:9-20. 2012
    ..Until the evidentiary gaps are filled, however, clinicians may choose to target therapeutics to individual patients whose genetic background indicates that they stand to benefit the most from pharmacogenetic testing...
  3. pmc Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy
    Deepak Voora
    Institute for Genome Sciences and Policy, Duke University, 905 S Lasalle Dr, DUMC Box 3445, Durham, NC 27710, USA
    J Thromb Thrombolysis 33:246-57. 2012
    ..Despite suppression of COX-1 activity, NCDPF during aspirin therapy is predictably dynamic: those with heightened NCDPF continue to decline whereas those with low/normal NCDPF return to pre-aspirin levels over time...
  4. doi request reprint Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use
    Deepak Voora
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 162:166-72.e1. 2011
    ....
  5. pmc Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response
    Deepak Voora
    Division of Cardiovascular Medicine, the Institute for Genome and Science Policy, and the Center for Human Genetics, Duke University, Durham, NC 27708, USA
    Circ Cardiovasc Genet 1:100-6. 2008
    ..There is interindividual variation in low-density lipoprotein cholesterol (LDLc) lowering by statins and limited study into the genetic associations of the dose dependant LDLc lowering by statins...
  6. doi request reprint The pharmacogenetics of antiplatelet agents: towards personalized therapy?
    Tariq Ahmad
    Division of Cardiology, Duke University School of Medicine, 2400 Pratt Street, DUMC 3850, Durham, NC 27710, USA
    Nat Rev Cardiol 8:560-71. 2011
    ..Ongoing and future clinical trials might provide evidence to support a change in practice towards pharmacogenetic-based selection of antiplatelet therapy...
  7. pmc The SLCO1B1*5 genetic variant is associated with statin-induced side effects
    Deepak Voora
    Division of Cardiovascular Medicine, Duke University Medical Center, Durham, North Carolina 27708, USA
    J Am Coll Cardiol 54:1609-16. 2009
    ..We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects...
  8. pmc Evaluation of the PharmGKB knowledge base as a resource for efficiently assessing the clinical validity and utility of pharmacogenetic assays
    Kensaku Kawamoto
    Division of Clinical Informatics, Department of Community and Family Medicine, Duke University, Durham, NC, USA
    AMIA Annu Symp Proc 2009:307-11. 2009
    ..Thus, we conclude that PharmGKB can facilitate the systematic assessment of pharmacogenetic assays through the efficient identification of relevant peer-reviewed manuscripts...
  9. ncbi request reprint A hub for bench-to-bedside pharmacogenomic-based research
    Deepak Voora
    Institute for Genome Sciences and Policy, Center for Genomic Medicine, 101 Science Drive, Duke University, DUMC Box 3382, Durham, NC 27708, USA
    Pharmacogenomics 12:1095-8. 2011
    ..These new treatment paradigms can, potentially, ensure that the right dose of the right drug is prescribed to the right individual - an often stated goal of personalized medicine and pharmacogenomics...
  10. ncbi request reprint Preoperative CYP2D6 metabolism-dependent β-blocker use and mortality after coronary artery bypass grafting surgery
    Miklos D Kertai
    Division of Cardiothoracic Anesthesiology and Critical Care, Department of Anesthesiology, Duke University Medical Center, Durham, NC Electronic address
    J Thorac Cardiovasc Surg 147:1368-1375.e3. 2014
    ..The purpose of the present study was to assess the association between the preoperative use of BBs dependent on metabolism of the CYP2D6 isoenzyme with operative mortality after coronary artery bypass grafting surgery...
  11. doi request reprint Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation
    Thomas W Wallace
    Duke Center for Atrial Fibrillation, Cardiac Electrophysiology Section of the Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    J Cardiovasc Electrophysiol 21:849-52. 2010
    ..Catheter-directed atrial fibrillation (AF) ablation is contraindicated among patients with left atrial appendage (LAA) thrombus. The prevalence of LAA thrombus among fully anticoagulated patients undergoing AF ablation is unknown...